Skip to main content

Cambrian BioPharma Inc's Form 4 filing

Faeth Therapeutics, Inc. (FTH) · filed Dec 10, 2025

Accession no.
0000897069-25-001795
Filed
Dec 10, 2025
Trade date
Dec 9, 2025
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $54.6K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cambrian BioPharma IncCIK 000179740910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 9, 2025Common StockSSaleDisposed−3,105$8.59−$26,671.95158,254Direct
Dec 9, 2025Common StockSSaleDisposed−2,666$7.95−$21,194.7155,588Direct
Dec 9, 2025Common StockMOption exerciseAcquired+395$6.40+$2,528155,983DirectDuplicate filing
Dec 9, 2025Common StockSSaleDisposed−395$8.04−$3,175.8155,588Direct
Dec 9, 2025Common StockSSaleDisposed−446$7.92−$3,532.32155,142Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 9, 2025Common StockMOption exerciseDisposed−395$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)